Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update

OBJECTIVE: Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies h...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Drug Assess
Main Authors: Kaddoura, Rasha, Orabi, Bassant, Salam, Amar M.
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2020
Fag:
Cardiovascular Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7470150/
https://ncbi.nlm.nih.gov/pubmed/32939318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2020.1801452
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker